Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (July 2026)
23 slides from Evofem Biosciences's investor presentation, Jul 20, 2026
Slide 1: Investor Presentation July 2026
E¥OFEM BIOSCIENCES INVESTOR PRESENTATION JULY 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘This presentation contains forward looking statements within the meaning of The Piva Secures tigation Reform Act of 1995 and other federal securities laws. ln some cases, you ean identi forward looking statements by terms such 35 ‘may! wil’ “shoul” expect,” “plan, “alm, “
Slide 3: Evofem Is Leading the Revolution
EVOFEM IS LEADING THE REVOLUTION OTCID: EVFM U.S. biopharma company commercializing innovative products to address unmet needs in women’s sexual and reproductive Driving revenue growth from two FDA-appr health oved sexual health products: 1 ee First and only hormone-free, on demand prescription cont
Slide 4: 26.2M Potential PHEXX Users in the U.S.
26.2M POTENTIAL PHEXX USERS IN THE U.S.1 CONTRACEPTIVE USE AMONG WOMEN OF REPRODUCTIVE AGE (66 Women using Method, U.S, 2022-2023; 74,9 M Women Aged 15-49) 9.8 M women use non-hormonal contraceptives ‘x methods: PHEXX?, Female condom, diaphragm "Nor-Ri methods: male condom; withdrawal periodic absti
Slide 5: PHEXX: Hormone Free Contraception
PHEXX: HORMONE FREE CONTRACEPTION r° WHAT MAKES PHEXX SO SPECIAL? “ Vaginal pH Modulator Hormone-free = FDA-approved for prevention of pregnancy Can be used with other contraceptives? Woman-controlled Sie) Used only when you need it Box of 12 pre-filled applicators, individually wrapped for convenie
Slide 6: Every 1% Market Share in the U.S. Addressable Market
EVERY 1% MARKET SHARE IN THE U.S. ADDRESSABLE MARKET phe REPRESENTS SIGNIFICANT PHEXX NET PRODUCT SALES $380.28 GROSS WAC per box of 12 PHEXX applicators? ae > $349 M BOXES OF PHEXX dispensed (on avg.) PHEXX ANNUAL per woman each yea! NET SALES Gross-to-Net a =| > X 262,000 © per each 1% market pene
Slide 7: Five Consecutive Years of Net Sales Growth
FIVE CONSECUTIVE YEARS OF NET SALES GROWTH $19.4 $20.2 $18.2 $16.8 IN MILLIONS ~ $82 s — FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Launched PHEXK ‘Sept. 2020, ‘No marketing spend since Q4 2022
Slide 8: PHEXX Sales Coverage
PHEXX SALES COVERAGE Field Coverage (n=16) Virtual Coverage Strategic Initiatives 11@ Student Health & Residency Programs
Slide 9: Activating PHEXX Utilization with Select Patient Types
ACTIVATING PHEXX UTILIZATION WITH SELECT PATIENT TYPES Not using a prescription contraceptive Living with depression and anxiety Postpartum mother Struggles with her weight In need of non-systemic contraception Cancer survivor Wants non-hormonal
Slide 10: Creating the Vaginal pH Modulator Category
CREATING THE VAGINAL PH MODULATOR CATEGORY Changing the contraceptive counseling conversation to make it personal HORMONE FREE CONTAINS HORMONES BIRTH CONTROL, IS PERSONAL. WHICH METHOD" MEETS Your NEEDS?
Slide 11: Harnessing the Power of Social Media
HARNESSING THE POWER OF SOCIAL MEDIA Social media is an effective channel to reach women ages 18 to 49 * 39% of women ages 18 to 49 have seen / heard something on social media about birth control 1 * 19% talked to someone in their life about what they heard / saw Reach and impact even higher in the
Slide 12: "Say Vagina" Campaign
“SAY VAGINA” CAMPAIGN COMBAT MEDIA CENSORSHIP AND NORMALIZE USE OF PROPER MEDICAL TERMS IN WOMEN’S HEALTH Say Vagina Views Generated Through this bold public campaign Evofem shared content across our social media accounts in August 2025 educating people on the vagina and how to properly care for it.
Slide 13: Multichannel Marketing
MULTICHANNEL MARKETING Enhancing promotional reach with minimal spend by tapping into social media, key conference opportunities, and tactical collateral Hormone-Free Birth Control youn mind
Slide 14: SOLOSEC: Single-Dose Oral Treatment for Two Common Sexual Health Conditions
> SINGLE-DOSE ORAL TREATMENT FOR ——, SOIOSEC Two COMMON SEXUAL HEALTH CONDITIONS “7 seconde * Acquired in July 2024, re-launched in November 2024 * Synergistic sexual health product aligns with our strategic focus and leverages sales force SOLOSEC provides a complete course of treatment with just on
Slide 15: The GLP-1 Opportunity: $945 Million TAM
THE GLP-1 OPPORTUNITY: $945 MILLION TAM “15.77 M » x$266.20 Women of Reproductive Age in the U.S. report GLP-1 Usage +2 net to Evofem per 3.55 M Women box of 12 PHEXX ¥ on GLP-1s using OCs 2206785 ssseaoi6 These women are instructed to use a supplemental, hormone- free method for 4 weeks after initi
Slide 16: Strong IP with Multiple Orange Book-Listed Patents
STRONG IP WITH MULTIPLE ORANGE BOOK-LISTED PATENTS nn soloséc ° ~—= secnidazole Four Orange Book- listed patents afford protection into 2033 White paper by US regulatory expert* delineates hurdles to potential generic entry stemming from PHEXX’s localized MOA and absence of PK profile, preventing de
Slide 17: Improving Our Financials Through Three Ongoing Initiatives
IMPROVING OUR FINANCIALS THROUGH THREE ONGOING INITIATIVES 1. EXPANDING REVENUE STREAM WITH EX-U.S. SALES 2. LOWERING SOLOSEC COGS * Goal — reduce SOLOSEC COGS by 55% to 60% starting 2027 3. LOWERING PHEXX COGS * Goal — reduce PHEXX COGS by 55% to 60% with new manufacturer, once FDA-cleared
Slide 18: Expanding Globally
EXPANDING GLOBALLY FIRST OUS TERRITORY: MIDDLE EAST/NORTH AFRICA (MENA) License and Supply agreements with Emirati health care company Pharma 1 Drug Store, LLC, for PHEXX and SOLOSEC signed July 2024 and May 2025, respectively. * Pharma 1 has exclusive commercialization rights in the Territory, and
Slide 19: First Market in Territory: United Arab Emirates
FIRST MARKET IN TERRITORY: UNITED ARAB EMIRATES (UAE) * 3.8 million women in UAE + + A 2019 contraceptive use study found 56% of women in UAE were using non-prescription methods (condom, withdrawal, sponge, calendar, and N-9 spermicide) 2 BIH OM + Application for marketing approval in UAE was submit
Slide 20: Expanding Globally: Sub-Saharan Africa
EXPANDING GLOBALLY SUB-SAHARAN AFRICA solosec Distribution agreement with Clovis Davis Pharmaceuticals signed April 2026 -——= secnidazole * Clovis Davis will lead the distribution, promotion, marketing, and sales of SOLOSEC within the Territory. * Evofem will supply manufactured goods at cost-plus,
Slide 21: Lowering PHEXX COGS
LOWERING PHEXX COGS Identified and engaged an OUS manufacturer for PHEXX in 2025. PHEXX COGS are expected to decrease by 55% to 60% from current levels once we are selling goods produced by new manufacturer. \ | [ \ | \ Z Process Timin: * Tech transfer to new manufacturer underway * Manufacture vali
Slide 22: Lowering SOLOSEC COGS
LOWERING SOLOSEC COGS Evofem is currently reactivating the SOLOSEC supply chain SOLOSEC COGS are expected to be 55% to 60% lower once we transition from selling legacy product to new-made goods Process Timin, ¥Source API supply complete * Receive raw secnidazole Q4 2026 * Manufacture SOLOSEC granule
Slide 23: In Summary
IN SUMMARY We are executing our strategy to improve women’s lives through innovative sexual and reproductive health products that address unmet and underserved medical needs fer The first and only FDA-approved hormone-free, on demand prescription contraceptive - simi vaginal gel - Approved and launc
Evofem Biosciences — Investor Presentation (July 2026) on 6ix